%0 Journal Article
%T 阿帕替尼单药或联合SOX方案及PD-1单抗治疗晚期胃癌的临床进展<br>Clinical Progress of Apatinib Monotherapy or Combination with SOX Regimen and PD-1 Monoclonal Antibody in the Treatment of Advanced Gastric Cancer
%A 刘晓萍
%A 李瑜英
%J Journal of Clinical Personalized Medicine
%P 280-284
%@ 2334-3443
%D 2024
%I Hans Publishing
%R 10.12677/jcpm.2024.32041
%X 我国胃癌负担极为沉重，具有分期晚、肿瘤负荷大、异质性强及预后差等特点，大多数患者确诊时已经处于晚期。晚期胃癌患者既往一线标准化疗带来的生存获益非常有限，随着抗肿瘤靶向药物的发展，抗血管靶向药物倍受关注。血管内皮生长因子受体抑制剂阿帕替尼，可靶向胃癌组织的新生血管，延缓其生长速度，从而抑制晚期胃癌的进一步恶化。本文将对阿帕替尼单药或联合SOX方案及PD-1单抗治疗晚期胃癌的临床进展作一综述。<br />
The burden of gastric cancer in China is extremely heavy, with the characteristics of late staging, large tumor burden, strong heterogeneity and poor prognosis, and most patients are already at an advanced stage when they are diagnosed. The survival benefit of the previous first-line standard chemotherapy in patients with advanced gastric cancer is very limited, and with the development of anti-tumor targeted drugs, anti-vascular targeted drugs have attracted much attention. Apatinib, a vascular endothelial growth factor receptor inhibitor, can target the new blood vessels of gastric cancer tissues, delay their growth rate, and thus inhibit the further progression of advanced gastric cancer. This article reviews the clinical progress of apatinib monotherapy or combination with SOX regimen and PD-1 monoclonal antibody in the treatment of advanced gastric cancer.
%K 阿帕替尼，SOX方案，PD-1单抗，晚期胃癌<br>Apatinib
%K SOX Regimen
%K PD-1 Monoclonal Antibody
%K Advanced Gastric Cancer
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=88878